# Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

> **NCT06899126** · PHASE3 · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 686 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Trastuzumab Deruxtecan
- **DRUG:** pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06899126
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-24
- **Primary completion:** 2030-03-05
- **Final completion:** 2032-07-05
- **Target enrollment:** 686 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06899126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06899126, "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06899126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*